On August 24, EVEREST MED rose 5.28% in regular trading, trading at HK$32.76/share, with turnover of HK$120 million.

The stock experienced a technical rebound after two consecutive sessions of correction totaling over 13%. Previously on August 20, shares surged more than 41% in a single day, driven by Moderna and Merck's announcement that their mRNA personalized cancer vaccine achieved positive results in its first Phase 3 clinical trial, combined with strong interim results showing revenue of RMB 1.148 billion, up 157% year-over-year, with losses narrowing 97.62%.

BOCOM International maintained its Buy rating on the stock with a target price of HK$66, citing strong sales growth of core product Nefecon (up 94% YoY to RMB 889 million in H1) and the company's efficient BD execution capabilities. The broker noted that proven commercialization infrastructure is expected to continue delivering value, though it trimmed revenue forecasts by 15-18% due to intensifying competition and short-term supply constraints.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)